Medicus Pharma

MDCX · NASDAQ

$2.50−$0.12 (−4.58%)TodayMarket closed · Oct 23, 7:54 PM ET

Prev close $2.62

Latest news

NewsOct 8, 9:39 AM ETAvi Kapoor
Dow Falls Over 100 Points; US Initial Jobless Claims Decline
Press releaseOct 8, 8:00 AM ETGlobe Newswire
Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value
NewsOct 8, 3:28 AM ETTanya Rawat
Medicus Pharma (MDCX) Shares Fall 24% After Hours: Here's Why
Press releaseSep 29, 7:30 AM ETGlobe Newswire
Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
NewsSep 21, 7:32 AM ETVandana Singh
Medicus Pharma Optimizes Portfolio Strategy With High-Value Focus
Press releaseSep 21, 7:30 AM ETGlobe Newswire
Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
Press releaseSep 10, 7:30 AM ETGlobe Newswire
Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
Press releaseSep 8, 7:30 AM ETGlobe Newswire
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company
NewsSep 3, 1:17 PM ETVandana Singh
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
NewsSep 3, 9:42 AM ETAvi Kapoor
Nasdaq Gains Over 200 Points; US Weekly Jobless Claims Edge Higher
Press releaseAug 12, 6:00 PM ETACCESS Newswire
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Press releaseAug 3, 7:30 AM ETGlobe Newswire
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
Press releaseJul 31, 7:30 AM ETGlobe Newswire
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
NewsJul 31, 7:15 AM ETVandana Singh
EXCLUSIVE: Medicus Pharma Launches Genomics-Guided Endometriosis Study In Abu Dhabi
Press releaseJul 27, 8:17 AM ETGlobe Newswire
Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
Press releaseJul 16, 7:30 AM ETGlobe Newswire
Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
Press releaseJun 22, 7:30 AM ETGlobe Newswire
Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026
Press releaseJun 15, 7:30 AM ETGlobe Newswire
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome
Press releaseJun 11, 7:30 AM ETGlobe Newswire
Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
Press releaseJun 8, 7:30 AM ETGlobe Newswire
Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
Press releaseJun 3, 8:00 AM ETGlobe Newswire
Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome
Press releaseMay 28, 8:00 AM ETGlobe Newswire
Medicus Pharma Announces $22 Million Non-Dilutive Financing
Press releaseMay 14, 4:30 PM ETGlobe Newswire
Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
Press releaseMay 6, 7:30 AM ETGlobe Newswire
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
NewsMay 6, 7:17 AM ETVandana Singh
EXCLUSIVE: Medicus Sees Strongest Efficacy At Higher Dose In Skin Cancer Study
Press releaseApr 27, 7:30 AM ETGlobe Newswire
Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill
Press releaseApr 17, 7:30 AM ETGlobe Newswire
Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome
NewsApr 16, 5:28 AM ETAvi Kapoor
Why J B Hunt Transport Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Press releaseApr 15, 7:30 AM ETGlobe Newswire
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression
NewsApr 15, 7:16 AM ETVandana Singh
EXCLUSIVE: Penny Stock Medicus Pharma Findings Support Potential In Women's Health Pipeline
Press releaseApr 6, 7:30 AM ETGlobe Newswire
Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention
NewsMar 6, 12:05 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
NewsMar 5, 12:45 PM ETAvi Kapoor
Crude Oil Surges 6%; BJ's Wholesale Club Earnings Top Views
NewsMar 5, 12:05 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsMar 4, 7:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsMar 3, 7:05 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
NewsMar 2, 4:06 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
NewsFeb 19, 7:05 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Dow Falls Over 100 Points; US Initial Jobless Claims Decline

Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value

Medicus Pharma (MDCX) Shares Fall 24% After Hours: Here's Why

Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer

Medicus Pharma Optimizes Portfolio Strategy With High-Value Focus

Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment

Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose

Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company

Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion

Nasdaq Gains Over 200 Points; US Weekly Jobless Claims Edge Higher

Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom

Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis

EXCLUSIVE: Medicus Pharma Launches Genomics-Guided Endometriosis Study In Abu Dhabi

Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome

Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention

Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026

Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome

Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program

Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission

Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome

Medicus Pharma Announces $22 Million Non-Dilutive Financing

Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

EXCLUSIVE: Medicus Sees Strongest Efficacy At Higher Dose In Skin Cancer Study

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Why J B Hunt Transport Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression

EXCLUSIVE: Penny Stock Medicus Pharma Findings Support Potential In Women's Health Pipeline

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

12 Health Care Stocks Moving In Friday's Intraday Session

Crude Oil Surges 6%; BJ's Wholesale Club Earnings Top Views

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session